BIO-TECHNE Corp TECH

The strongest current Bio-Techne fact is the Wilson Wolf contract trigger. The March 31, 2026 10-Q says the first part of the forward contract has been triggered after a milestone tied to approximately $92 million in annual revenue or $55 million in EBITDA before December 31, 2027. Because that first part has been triggered, the second part will automatically require Bio-Techne to acquire the remaining equity interest in Wilson Wolf on December 31, 2027, based on a revenue multiple. The filing also gives an acceleration test: approximately $226 million in annual revenue or $136 million in annual EBITDA. Source: Official SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/842023/000110465926056302/tech-20260331x10q.htm.

The supplied product rail shows Bio-Techne as an operating life-sciences company, not just a ticker with a laboratory accent. The February 11, 2026 8-K describes an Analytical Solutions Division role responsible for a portfolio of protein analysis instruments and immunoassays, with strategic initiatives, innovative platform launches and strong growth named in the release excerpt. The June 1 Form SD adds a supply-chain angle: most products Bio-Techne manufactures or contracts to manufacture do not contain conflict minerals. Those two filings put products, platforms and manufacturing discipline at the centre of the equity story. Sources: Official SEC EDGAR 8-K, https://www.sec.gov/Archives/edgar/data/842023/000110465926013412/tech-20260209x8k.htm; SEC EDGAR Form SD, https://www.sec.gov/Archives/edgar/data/842023/000110465926068957/tech-20260601xsd.htm.

The latest parsed financial rail is the 10-Q for the period ending March 31, 2026. It reports revenue from contracts with customers, excluding assessed tax, of $311.4 million; revenues of $311.4 million; operating income of $75.5 million; net income attributable to parent of $51.0 million; and diluted earnings per share of $0.32 on 157.4 million diluted weighted average shares. The same filing rail shows assets of $2.55 billion, stockholders' equity attributable to parent of $2.09 billion, cash and cash equivalents of $209.8 million, inventory net of $201.2 million, an increase in inventories of $12.5 million, net cash provided by operating activities of $196.7 million and payments to acquire property, plant and equipment of $20.4 million. Source: Official SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/842023/000110465926056302/tech-20260331x10q.htm.

No chart route or TradingView source is supplied in this evidence rail, so the market mechanism here is filing-led rather than candle-led. The sourced public record consists of the May 6, 2026 10-Q, the May 6 8-K attaching press releases for quarterly and nine-month results and a cash dividend, the February 11 8-K, the June 1 Form SD, multiple Form 4 filings dated May 7, May 12 and June 4, a May 8 Form 144, the SEC filing index, SEC submissions JSON and SEC companyfacts JSON. The rail does not prove price levels, volume, support, resistance or moving-average behaviour. Sources: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=842023; SEC submissions JSON, https://data.sec.gov/submissions/CIK0000842023.json.

What changed is concrete but not theatrical. On May 6, Bio-Techne filed an 8-K saying a press release described results of operations for the quarter and nine months ended March 31, 2026 and financial condition as of that date, and another press release announced a cash dividend. The same date brought the 10-Q financial rail. Then came a May 8 Form 144, a May 12 Form 4, a June 1 Form SD and a June 4 Form 4. The supplied list also includes two May 7 Form 4 filings. These named developments confirm public filing activity, but this pack does not parse the transaction-level detail inside the Form 4 or Form 144 documents. Sources: Official SEC EDGAR 8-K, https://www.sec.gov/Archives/edgar/data/842023/000110465926055887/tech-20260506x8k.htm; SEC EDGAR Form 144, https://www.sec.gov/Archives/edgar/data/842023/000195004726004265/xsl144X01/primary_doc.xml.

The file would deepen with parsed segment performance, dividend amount, guidance, full Form 4 and Form 144 transaction detail, and a supplied chart route. Until then, the cleanest tension is between an operating company with $311.4 million of latest quarterly revenue, $51.0 million of net income attributable to parent and $196.7 million of operating cash flow on the supplied 10-Q rail, and a Wilson Wolf contract path that can force or accelerate a remaining-equity acquisition under explicit revenue or EBITDA tests. Source: Official SEC EDGAR 10-Q, https://www.sec.gov/Archives/edgar/data/842023/000110465926056302/tech-20260331x10q.htm.